RNA Therapeutics Market by Product (Vaccines, Drugs), Type (mRNA Therapeutics, RNA Interference, Antisense Oligonucleotides), Indication (Infectious Diseases, Rare Genetic Diseases), End User (Hospitals & Clinics) - Global Forecast to 2028
The RNA therapeutics market is projected to grow from USD 13.7 billion in 2023 to USD 18.0 billion by 2028 at a CAGR of 5.6%. The key factors driving the overall market growth include an increase in the number of collaborations and partnerships among market players as well as RNA technology manufacturers, an increase in applications of different types of RNA therapeutics (such as RNA aptamers, siRNA, small-activating RNA), and the rapid emergency use authorizations and approvals for COVID-19 booster vaccines. The emergence of small activating RNAs (siRNAs) and circular RNAs (circRNAs) has expanded the scope of RNA therapeutics.
“RNA drugs to witness the highest growth during the forecast period.”
Based on product, the RNA therapeutics market is segmented into drugs and vaccines. In 2022, vaccines represented the majority of the market share, whereas the RNA drugs segment registered the highest growth rate during the forecast period (2023-2028). The growth of the RNA therapeutics drugs market is propelled by a surge in technological advancements in RNA synthesis and drug delivery. The increasing number of FDA approvals for RNA-based drugs and robust increase in the pipeline are attributive to the segment’s lucrative growth. Regulatory approvals of RNA-based drugs, such as Patisiran, Lumasiran, and Viltolarsen, and their successful commercialization have encouraged several therapeutics manufacturers to invest in this space.
“The mRNA therapeutics segment accounted for the largest share in the RNA therapeutics market in 2022.”
Based on the type, the RNA therapeutics market is segmented into RNA interference (RNAi) therapeutics, mRNA therapeutics, antisense oligonucleotide (ASO) therapeutics, and other therapeutics. The mRNA therapeutics segment accounted for the largest share of the RNA therapeutics market in 2022. The success of mRNA-based COVID-19 vaccines has also demonstrated the potential of mRNA technology in developing effective vaccines against infectious diseases, leading to increased interest and investment in mRNA therapeutics. In August 2023, CARsgen Therapeutics Holdings collaborated with Moderna, Inc. to investigate CARsgen's investigational Claudin18.2 CAR T-cell product candidate (CT041) in combination with Moderna’s investigational Claudin18.2 mRNA cancer vaccine.
“Rare genetic/hereditary diseases have emerged as a lucrative segment in the RNA therapeutics market.”
Based on the indication, the RNA therapeutics market is segmented into infectious diseases, rare genetic diseases/hereditary diseases, and other indications. Rare genetic diseases, often characterized by their limited prevalence and challenging treatment paradigms, create opportunities for the innovative potential of RNA-based interventions. RNA therapeutics offer a unique avenue to address these rare genetic disorders by precisely targeting the underlying genetic mutations that are responsible for the diseases. Through techniques such as gene silencing using small interfering RNAs (siRNAs) or gene editing using CRISPR/Cas9, RNA therapeutics correct or mitigate the genetic abnormalities causing these conditions.
Europe dominates the global RNA therapeutics market throughout the forecast period.
The global RNA therapeutics market is segmented into four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World. Europe leads the market for RNA vaccines, with the highest share of revenue in this segment in 2022. North America has emerged as the fastest-growing region from 2023 to 2028. The collective revenue share of Europe, across both RNA vaccines and RNA drugs, is highest in 2022, and this is set to continue through the forecast period.
Breakdown of supply-side primary interviews by company type, designation, and region:
This report studies the RNA therapeutics market based on product, type, indication, end user, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total RNA therapeutics market. The report forecasts the revenue of the market segments with respect to four major regions.
Reasons to Buy the Report:
The report provides insights on the following pointers:
.
“RNA drugs to witness the highest growth during the forecast period.”
Based on product, the RNA therapeutics market is segmented into drugs and vaccines. In 2022, vaccines represented the majority of the market share, whereas the RNA drugs segment registered the highest growth rate during the forecast period (2023-2028). The growth of the RNA therapeutics drugs market is propelled by a surge in technological advancements in RNA synthesis and drug delivery. The increasing number of FDA approvals for RNA-based drugs and robust increase in the pipeline are attributive to the segment’s lucrative growth. Regulatory approvals of RNA-based drugs, such as Patisiran, Lumasiran, and Viltolarsen, and their successful commercialization have encouraged several therapeutics manufacturers to invest in this space.
“The mRNA therapeutics segment accounted for the largest share in the RNA therapeutics market in 2022.”
Based on the type, the RNA therapeutics market is segmented into RNA interference (RNAi) therapeutics, mRNA therapeutics, antisense oligonucleotide (ASO) therapeutics, and other therapeutics. The mRNA therapeutics segment accounted for the largest share of the RNA therapeutics market in 2022. The success of mRNA-based COVID-19 vaccines has also demonstrated the potential of mRNA technology in developing effective vaccines against infectious diseases, leading to increased interest and investment in mRNA therapeutics. In August 2023, CARsgen Therapeutics Holdings collaborated with Moderna, Inc. to investigate CARsgen's investigational Claudin18.2 CAR T-cell product candidate (CT041) in combination with Moderna’s investigational Claudin18.2 mRNA cancer vaccine.
“Rare genetic/hereditary diseases have emerged as a lucrative segment in the RNA therapeutics market.”
Based on the indication, the RNA therapeutics market is segmented into infectious diseases, rare genetic diseases/hereditary diseases, and other indications. Rare genetic diseases, often characterized by their limited prevalence and challenging treatment paradigms, create opportunities for the innovative potential of RNA-based interventions. RNA therapeutics offer a unique avenue to address these rare genetic disorders by precisely targeting the underlying genetic mutations that are responsible for the diseases. Through techniques such as gene silencing using small interfering RNAs (siRNAs) or gene editing using CRISPR/Cas9, RNA therapeutics correct or mitigate the genetic abnormalities causing these conditions.
Europe dominates the global RNA therapeutics market throughout the forecast period.
The global RNA therapeutics market is segmented into four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World. Europe leads the market for RNA vaccines, with the highest share of revenue in this segment in 2022. North America has emerged as the fastest-growing region from 2023 to 2028. The collective revenue share of Europe, across both RNA vaccines and RNA drugs, is highest in 2022, and this is set to continue through the forecast period.
Breakdown of supply-side primary interviews by company type, designation, and region:
- By Respondent: Supply Side (70%), Demand side (30%)
- By Designation: C-level (55%), Director-level (20%), and Others (25%)
- By Region: North America (50%), Europe (20%), AsiaPacific (20%), and Rest of the World(10%)
- Moderna, Inc. (US)
- Alnylam Pharmaceuticals, Inc. (US)
- Pfizer Inc. (US)
- Novartis AG (Switzerland)
- Ionis Pharmaceuticals, Inc. (US)
- Sarepta Therapeutics, Inc. (US)
- Sanofi (France)
- Arrowhead Pharmaceuticals, Inc. (US)
- BioNtech SE (Germany)
- Orna Therapeutics (US)
- CRISPR Therapeutics (Switzerland)
- Silence Therapeutics (UK)
- Astellas Pharma Inc. (Japan)
- CureVac SE (Germany)
- Sirnaomics (US)
- Arcturus Therapeutics Inc. (US)
- Arbutus Biopharma (US)
This report studies the RNA therapeutics market based on product, type, indication, end user, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total RNA therapeutics market. The report forecasts the revenue of the market segments with respect to four major regions.
Reasons to Buy the Report:
The report provides insights on the following pointers:
.
- Market Drivers: The key factors driving the overall market growth include an increase in the number of collaborations and partnerships among market players as well as RNA technology manufacturers, an increase in applications of different types of RNA therapeutics and the rapid emergency use authorizations and approvals for COVID-19 booster vaccines.
- Market Penetration: Comprehensive information on RNA therapeutics offered by the top 17-20 players in the market. The report analyzes the RNA therapeutics market by product, type, indication, end user, and region.
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various products/types of RNA therapeutics/end users across key geographic regions.
- Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the gene editing market
- Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the RNA therapeutics market
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 RESEARCH LIMITATIONS
1.6 STAKEHOLDERS
1.6.1 RECESSION IMPACT: RNA THERAPEUTICS MARKET
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 BREAKDOWN OF PRIMARIES: RNA THERAPEUTICS MARKET
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 3 RNA THERAPEUTICS MARKET SIZE ESTIMATION (SUPPLY SIDE ANALYSIS), 2022
FIGURE 4 MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION, 2022
2.2.1 INSIGHTS FROM PRIMARY EXPERTS
FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
2.3 MARKET GROWTH RATE PROJECTION
FIGURE 6 RNA THERAPEUTICS MARKET (SUPPLY SIDE): CAGR PROJECTIONS
FIGURE 7 GROWTH ANALYSIS OF DEMAND SIDE DRIVERS: RNA THERAPEUTICS MARKET
2.4 MARKET ESTIMATION AND DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.5 STUDY ASSUMPTIONS
2.6 RISK ANALYSIS
2.7 IMPACT OF ECONOMIC RECESSION ON RNA THERAPEUTICS MARKET
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
3 EXECUTIVE SUMMARY
FIGURE 9 RNA THERAPEUTICS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
FIGURE 10 RNA THERAPEUTICS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 11 RNA THERAPEUTICS MARKET, BY INDICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 12 RNA THERAPEUTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 13 REGIONAL SNAPSHOT: RNA THERAPEUTICS MARKET
4 PREMIUM INSIGHTS
4.1 RNA THERAPEUTICS MARKET OVERVIEW
FIGURE 14 GROWING PARTNERSHIPS AND COLLABORATIONS AMONG KEY PLAYERS TO DRIVE MARKET
4.2 NORTH AMERICA: RNA THERAPEUTICS MARKET SHARE, BY PRODUCT AND COUNTRY (2022)
FIGURE 15 VACCINES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN RNA THERAPEUTICS MARKET IN 2022
4.3 NORTH AMERICA: RNA THERAPEUTICS MARKET, BY INDICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 16 INFECTIOUS DISEASES TO DOMINATE NORTH AMERICAN RNA THERAPEUTICS MARKET DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 17 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: RNA THERAPEUTICS MARKET
TABLE 4 IMPACT ANALYSIS: RNA THERAPEUTICS MARKET
5.2.1 DRIVERS
5.2.1.1 Increasing partnerships and collaborations between market players and RNA technology manufacturers
5.2.1.2 Increasing number of novel modalities for RNA therapeutics
5.2.1.3 Growing number of emergency use authorizations and approvals for COVID-19 booster vaccines
5.2.2 RESTRAINTS
5.2.2.1 Discontinuation or recalls of RNA therapeutic products
TABLE 5 LIST OF RNA THERAPEUTICS FOR WHICH CLINICAL DEVELOPMENT WAS HALTED
5.2.3 OPPORTUNITIES
5.2.3.1 Higher progress in development of RNA aptamer-based therapeutics
TABLE 6 RNA APTAMERS UNDER CLINICAL DEVELOPMENT
5.2.4 CHALLENGES
5.2.4.1 Rapid degradation by ubiquitous RNases in environment and tissues with strong immunogenicity of exogenous RNA
5.3 TECHNOLOGY ANALYSIS (RNA VACCINE AND THERAPY MANUFACTURING)
5.3.1 PARAMETERS OF MANUFACTURING
5.3.2 CIRCULAR RNA ENGINEERING
5.4 PIPELINE ANALYSIS
FIGURE 18 PIPELINE THERAPIES, BY CATEGORY, 2022
5.4.1 PIPELINE ANALYSIS FOR KEY MARKET PLAYERS (TOP 5)
5.4.1.1 Moderna, Inc.
TABLE 7 PIPELINE CANDIDATES OF MODERNA, INC.
5.4.1.2 Pfizer, Inc.
TABLE 8 PIPELINE CANDIDATES OF PFIZER INC.
5.4.1.3 Alnylam Pharmaceuticals, Inc.
TABLE 9 PIPELINE CANDIDATES OF ALNYLAM PHARMACEUTICALS, INC.
5.4.1.4 Novartis AG
TABLE 10 PIPELINE CANDIDATES OF NOVARTIS AG
5.4.1.5 Ionis Pharmaceuticals, Inc.
TABLE 11 PIPELINE CANDIDATES OF IONIS PHARMACEUTICALS, INC.
5.5 PORTER’S FIVE FORCES ANALYSIS
TABLE 12 PORTER’S FIVE FORCES ANALYSIS: RNA THERAPEUTICS MARKET
5.5.1 THREAT OF NEW ENTRANTS
5.5.2 THREAT OF SUBSTITUTES
5.5.3 BARGAINING POWER OF BUYERS
5.5.4 BARGAINING POWER OF SUPPLIERS
5.5.5 INTENSITY OF COMPETITIVE RIVALRY
5.6 REGULATORY ANALYSIS
TABLE 13 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.7 VALUE CHAIN ANALYSIS
FIGURE 19 VALUE CHAIN ANALYSIS OF RNA THERAPEUTICS MARKET: R&D AND MANUFACTURING PHASES ADD MAXIMUM VALUE
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 20 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.9 KEY STAKEHOLDERS AND BUYING CRITERIA
5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RNA-BASED THERAPEUTICS
5.9.2 BUYING CRITERIA FOR RNA THERAPEUTIC PRODUCTS/MEDICINES
FIGURE 22 KEY BUYING CRITERIA FOR END USERS
5.10 PRICING ANALYSIS
5.10.1 PRICING ANALYSIS FOR FDA-APPROVED RNA THERAPEUTICS, BY PRODUCT
TABLE 17 AVERAGE SELLING PRICE FOR RNA VACCINES AND DRUGS, BY REGION
5.10.2 PRICING TREND ANALYSIS: RNA VACCINES AND DRUGS
5.11 KEY CONFERENCES AND EVENTS (2023–2024)
TABLE 18 KEY CONFERENCES AND EVENTS IN RNA THERAPEUTICS MARKET (2023–2024)
5.12 ECOSYSTEM MARKET MAP
6 RNA THERAPEUTICS MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 19 RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
6.2 VACCINES
6.2.1 INCREASED NUMBER OF APPROVALS AND HIGHER INVESTMENTS FOR COVID-19 BOOSTER VACCINES TO DRIVE MARKET
TABLE 20 RNA THERAPEUTICS MARKET FOR VACCINES, BY REGION, 2021–2028 (USD MILLION)
TABLE 21 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 22 EUROPE: RNA THERAPEUTICS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 23 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
6.3 DRUGS
6.3.1 GROWING FUNDING AND INVESTMENTS IN RNA THERAPEUTICS RESEARCH TO DRIVE MARKET
TABLE 24 RNA THERAPEUTICS MARKET FOR DRUGS, BY REGION, 2021–2028 (USD MILLION)
TABLE 25 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 26 EUROPE: RNA THERAPEUTICS MARKET FOR DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 27 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
7 RNA THERAPEUTICS MARKET, BY TYPE
7.1 INTRODUCTION
TABLE 28 RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION)
7.2 MRNA THERAPEUTICS
7.2.1 INCREASING INVESTMENTS FOR COVID-19 MRNA VACCINES TO DRIVE MARKET
TABLE 29 RNA THERAPEUTICS MARKET FOR MRNA THERAPEUTICS, BY REGION, 2021–2028 (USD MILLION)
TABLE 30 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR MRNA THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 31 EUROPE: RNA THERAPEUTICS MARKET FOR MRNA THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 32 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR MRNA THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION)
7.3 RNA INTERFERENCE (RNAI) THERAPEUTICS
7.3.1 INCREASING NUMBER OF APPROVALS FOR SIRNA THERAPEUTICS BY US FDA TO DRIVE MARKET
TABLE 33 RNA THERAPEUTICS MARKET FOR RNA INTERFERENCE (RNAI) THERAPEUTICS, BY REGION, 2021–2028 (USD MILLION)
TABLE 34 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR RNA INTERFERENCE (RNAI) THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 35 EUROPE: RNA THERAPEUTICS MARKET FOR RNA INTERFERENCE (RNAI) THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 36 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR RNA INTERFERENCE (RNAI) THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION)
7.4 ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS
7.4.1 INCREASED NUMBER OF CHEMICAL MODIFICATIONS AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
TABLE 37 RNA THERAPEUTICS MARKET FOR ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS, BY REGION, 2021–2028 (USD MILLION)
TABLE 38 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 39 EUROPE: RNA THERAPEUTICS MARKET FOR ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 40 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION)
7.5 OTHER THERAPEUTICS
8 RNA THERAPEUTICS MARKET, BY INDICATION
8.1 INTRODUCTION
TABLE 41 RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
8.2 INFECTIOUS DISEASES
8.2.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES AND GROWING INVESTMENTS IN R&D TO DRIVE MARKET
TABLE 42 RNA THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION)
TABLE 43 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 44 EUROPE: RNA THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 45 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
8.3 RARE GENETIC/HEREDITARY DISEASES
8.3.1 TECHNOLOGICAL INNOVATION AND INCREASED DEMAND FOR PERSONALIZED MEDICINES TO DRIVE MARKET
TABLE 46 RNA THERAPEUTICS MARKET FOR RARE GENETIC/HEREDITARY DISEASES, BY REGION, 2021–2028 (USD MILLION)
TABLE 47 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR RARE GENETIC/HEREDITARY DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 48 EUROPE: RNA THERAPEUTICS MARKET FOR RARE GENETIC/HEREDITARY DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 49 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR RARE GENETIC/HEREDITARY DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
8.4 OTHER INDICATIONS
TABLE 50 RNA THERAPEUTICS MARKET FOR OTHER INDICATIONS, BY REGION, 2021–2028 (USD MILLION)
TABLE 51 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 52 EUROPE: RNA THERAPEUTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 53 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
9 RNA THERAPEUTICS MARKET, BY END USER
9.1 INTRODUCTION
TABLE 54 RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
9.2 HOSPITALS AND CLINICS
9.2.1 INCREASED PREVALENCE OF CHRONIC DISEASES AND HIGHER EFFICACY OF RNA-BASED THERAPIES TO DRIVE MARKET
TABLE 55 RNA THERAPEUTICS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021–2028 (USD MILLION)
TABLE 56 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 57 EUROPE: RNA THERAPEUTICS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 58 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)
9.3 RESEARCH SETTINGS
9.3.1 HIGHER THERAPEUTIC POTENTIAL OF RNA TECHNOLOGY TO CREATE NEW OPPORTUNITIES IN MEDICAL RESEARCH
TABLE 59 RNA THERAPEUTICS MARKET FOR RESEARCH SETTINGS, BY REGION, 2021–2028 (USD MILLION)
TABLE 60 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR RESEARCH SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 61 EUROPE: RNA THERAPEUTICS MARKET FOR RESEARCH SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 62 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR RESEARCH SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)
10 RNA THERAPEUTICS MARKET, BY REGION
10.1 INTRODUCTION
TABLE 63 RNA THERAPEUTICS MARKET, BY REGION, 2021–2028 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 23 NORTH AMERICA: RNA THERAPEUTICS MARKET SNAPSHOT
TABLE 64 NORTH AMERICA: RNA THERAPEUTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 65 NORTH AMERICA: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 66 NORTH AMERICA: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 67 NORTH AMERICA: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 68 NORTH AMERICA: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.1 NORTH AMERICA: RECESSION IMPACT
10.2.2 US
10.2.2.1 Growing technological innovation in RNA delivery systems and rising investments in biopharmaceutical research to drive market
TABLE 69 LIST OF RECENT RNA THERAPEUTICS APPROVED BY FDA
TABLE 70 US: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 71 US: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 72 US: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 73 US: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.3 CANADA
10.2.3.1 Increasing government initiatives and investments for life science research to drive market
TABLE 74 CANADA: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 75 CANADA: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 76 CANADA: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 77 CANADA: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3 EUROPE
TABLE 78 EUROPE: RNA THERAPEUTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 79 EUROPE: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 80 EUROPE: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 81 EUROPE: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 82 EUROPE: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.1 EUROPE: RECESSION IMPACT
10.3.2 GERMANY
10.3.2.1 Rising number of market players and growing public and private funding for research activities to drive market
TABLE 83 GERMANY: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 84 GERMANY: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 85 GERMANY: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 86 GERMANY: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Growing pharmaceutical manufacturing industry and increasing number of clinical trials for oncology to drive market
TABLE 87 FRANCE: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 88 FRANCE: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 89 FRANCE: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 90 FRANCE: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.4 UK
10.3.4.1 Higher R&D investment by pharmaceutical companies for RNA-based drug discovery to drive market
TABLE 91 UK: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 92 UK: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 93 UK: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 94 UK: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.5 REST OF EUROPE
TABLE 95 REST OF EUROPE: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 96 REST OF EUROPE: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 97 REST OF EUROPE: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 98 REST OF EUROPE: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 24 ASIA PACIFIC: RNA THERAPEUTICS MARKET SNAPSHOT
TABLE 99 ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 100 ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 101 ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 102 ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 103 ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.1 ASIA PACIFIC: RECESSION IMPACT
10.4.2 JAPAN
10.4.2.1 Increasing geriatric population and rising government initiatives for drug innovation to drive market
TABLE 104 JAPAN: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 105 JAPAN: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 106 JAPAN: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 107 JAPAN: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.3 CHINA
10.4.3.1 Low manufacturing costs and increased number of R&D activities to drive market
TABLE 108 CHINA: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 109 CHINA: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 110 CHINA: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 111 CHINA: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.4 SOUTH KOREA
10.4.4.1 Increasing number of government initiatives and growing R&D activities for RNA therapeutics to drive market
TABLE 112 SOUTH KOREA: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 113 SOUTH KOREA: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 114 SOUTH KOREA: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 115 SOUTH KOREA: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.5 REST OF ASIA PACIFIC
TABLE 116 REST OF ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 117 REST OF ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 118 REST OF ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 119 REST OF ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.5 REST OF THE WORLD
TABLE 120 REST OF THE WORLD: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 121 REST OF THE WORLD: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 122 REST OF THE WORLD: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 123 REST OF THE WORLD: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS IN RNA THERAPEUTICS MARKET
FIGURE 25 KEY PLAYER STRATEGIES IN RNA THERAPEUTICS MARKET, 2021–2023
11.3 MARKET SHARE ANALYSIS
FIGURE 26 MARKET SHARE ANALYSIS OF TOP 3 PLAYERS IN RNA THERAPEUTICS MARKET, 2022
TABLE 124 DEGREE OF COMPETITION: RNA THERAPEUTICS MARKET
11.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 27 REVENUE SHARE ANALYSIS OF TOP 4 PLAYERS IN RNA THERAPEUTICS MARKET, 2020–2022
11.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 28 COMPANY EVALUATION MATRIX FOR KEY PLAYERS: RNA THERAPEUTICS MARKET, 2022
11.6 COMPANY EVALUATION MATRIX FOR START-UPS/SMES
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 DYNAMIC COMPANIES
11.6.4 RESPONSIVE COMPANIES
FIGURE 29 COMPANY EVALUATION MATRIX FOR START-UPS/SMES: RNA THERAPEUTICS MARKET, 2022
11.7 COMPETITIVE BENCHMARKING
TABLE 125 DETAILED LIST OF KEY START-UPS/SMES: RNA THERAPEUTICS MARKET
11.8 COMPETITIVE SCENARIOS AND TRENDS
11.8.1 KEY PRODUCT APPROVALS
TABLE 126 KEY PRODUCT APPROVALS, JANUARY 2021–AUGUST 2023
11.8.2 KEY DEALS
TABLE 127 KEY DEALS, JANUARY 2021–AUGUST 2023
11.8.3 OTHER KEY DEVELOPMENTS
TABLE 128 OTHER KEY DEVELOPMENTS, JANUARY 2021–AUGUST 2023
12 COMPANY PROFILES
(Business overview, Products offered, Recent Developments, MNM view)*
12.1 KEY PLAYERS
12.1.1 MODERNA, INC.
TABLE 129 MODERNA, INC.: COMPANY OVERVIEW
FIGURE 30 MODERNA, INC.: COMPANY SNAPSHOT (2022)
12.1.2 ALNYLAM PHARMACEUTICALS, INC.
TABLE 130 ALNYLAM PHARMACEUTICALS, INC.: COMPANY OVERVIEW
FIGURE 31 ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2022)
12.1.3 NOVARTIS AG
TABLE 131 NOVARTIS AG: COMPANY OVERVIEW
FIGURE 32 NOVARTIS AG: COMPANY SNAPSHOT (2022)
12.1.4 IONIS PHARMACEUTICALS, INC.
TABLE 132 IONIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW
FIGURE 33 IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2022)
12.1.5 SAREPTA THERAPEUTICS, INC.
TABLE 133 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW
FIGURE 34 SAREPTA THERAPEUTICS, INC.: COMPANY SNAPSHOT (2022)
12.1.6 SANOFI
TABLE 134 SANOFI: COMPANY OVERVIEW
FIGURE 35 SANOFI: COMPANY SNAPSHOT (2022)
12.1.7 PFIZER INC.
TABLE 135 PFIZER INC.: COMPANY OVERVIEW
FIGURE 36 PFIZER INC.: COMPANY SNAPSHOT (2022)
12.2 OTHER PLAYERS
12.2.1 ARROWHEAD PHARMACEUTICALS, INC.
12.2.2 BIONTECH SE
12.2.3 ORNA THERAPEUTICS
12.2.4 CRISPR THERAPEUTICS
12.2.5 SILENCE THERAPEUTICS
12.2.6 ASTELLAS PHARMA INC.
12.2.7 CUREVAC SE
12.2.8 SIRNAOMICS
12.2.9 ARCTURUS THERAPEUTICS, INC.
12.2.10 ARBUTUS BIOPHARMA
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
13 APPENDIX
13.1 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.2 CUSTOMIZATION OPTIONS
13.3 RELATED REPORTS
13.4 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 RESEARCH LIMITATIONS
1.6 STAKEHOLDERS
1.6.1 RECESSION IMPACT: RNA THERAPEUTICS MARKET
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 BREAKDOWN OF PRIMARIES: RNA THERAPEUTICS MARKET
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 3 RNA THERAPEUTICS MARKET SIZE ESTIMATION (SUPPLY SIDE ANALYSIS), 2022
FIGURE 4 MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION, 2022
2.2.1 INSIGHTS FROM PRIMARY EXPERTS
FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
2.3 MARKET GROWTH RATE PROJECTION
FIGURE 6 RNA THERAPEUTICS MARKET (SUPPLY SIDE): CAGR PROJECTIONS
FIGURE 7 GROWTH ANALYSIS OF DEMAND SIDE DRIVERS: RNA THERAPEUTICS MARKET
2.4 MARKET ESTIMATION AND DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.5 STUDY ASSUMPTIONS
2.6 RISK ANALYSIS
2.7 IMPACT OF ECONOMIC RECESSION ON RNA THERAPEUTICS MARKET
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
3 EXECUTIVE SUMMARY
FIGURE 9 RNA THERAPEUTICS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
FIGURE 10 RNA THERAPEUTICS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 11 RNA THERAPEUTICS MARKET, BY INDICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 12 RNA THERAPEUTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 13 REGIONAL SNAPSHOT: RNA THERAPEUTICS MARKET
4 PREMIUM INSIGHTS
4.1 RNA THERAPEUTICS MARKET OVERVIEW
FIGURE 14 GROWING PARTNERSHIPS AND COLLABORATIONS AMONG KEY PLAYERS TO DRIVE MARKET
4.2 NORTH AMERICA: RNA THERAPEUTICS MARKET SHARE, BY PRODUCT AND COUNTRY (2022)
FIGURE 15 VACCINES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN RNA THERAPEUTICS MARKET IN 2022
4.3 NORTH AMERICA: RNA THERAPEUTICS MARKET, BY INDICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 16 INFECTIOUS DISEASES TO DOMINATE NORTH AMERICAN RNA THERAPEUTICS MARKET DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 17 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: RNA THERAPEUTICS MARKET
TABLE 4 IMPACT ANALYSIS: RNA THERAPEUTICS MARKET
5.2.1 DRIVERS
5.2.1.1 Increasing partnerships and collaborations between market players and RNA technology manufacturers
5.2.1.2 Increasing number of novel modalities for RNA therapeutics
5.2.1.3 Growing number of emergency use authorizations and approvals for COVID-19 booster vaccines
5.2.2 RESTRAINTS
5.2.2.1 Discontinuation or recalls of RNA therapeutic products
TABLE 5 LIST OF RNA THERAPEUTICS FOR WHICH CLINICAL DEVELOPMENT WAS HALTED
5.2.3 OPPORTUNITIES
5.2.3.1 Higher progress in development of RNA aptamer-based therapeutics
TABLE 6 RNA APTAMERS UNDER CLINICAL DEVELOPMENT
5.2.4 CHALLENGES
5.2.4.1 Rapid degradation by ubiquitous RNases in environment and tissues with strong immunogenicity of exogenous RNA
5.3 TECHNOLOGY ANALYSIS (RNA VACCINE AND THERAPY MANUFACTURING)
5.3.1 PARAMETERS OF MANUFACTURING
5.3.2 CIRCULAR RNA ENGINEERING
5.4 PIPELINE ANALYSIS
FIGURE 18 PIPELINE THERAPIES, BY CATEGORY, 2022
5.4.1 PIPELINE ANALYSIS FOR KEY MARKET PLAYERS (TOP 5)
5.4.1.1 Moderna, Inc.
TABLE 7 PIPELINE CANDIDATES OF MODERNA, INC.
5.4.1.2 Pfizer, Inc.
TABLE 8 PIPELINE CANDIDATES OF PFIZER INC.
5.4.1.3 Alnylam Pharmaceuticals, Inc.
TABLE 9 PIPELINE CANDIDATES OF ALNYLAM PHARMACEUTICALS, INC.
5.4.1.4 Novartis AG
TABLE 10 PIPELINE CANDIDATES OF NOVARTIS AG
5.4.1.5 Ionis Pharmaceuticals, Inc.
TABLE 11 PIPELINE CANDIDATES OF IONIS PHARMACEUTICALS, INC.
5.5 PORTER’S FIVE FORCES ANALYSIS
TABLE 12 PORTER’S FIVE FORCES ANALYSIS: RNA THERAPEUTICS MARKET
5.5.1 THREAT OF NEW ENTRANTS
5.5.2 THREAT OF SUBSTITUTES
5.5.3 BARGAINING POWER OF BUYERS
5.5.4 BARGAINING POWER OF SUPPLIERS
5.5.5 INTENSITY OF COMPETITIVE RIVALRY
5.6 REGULATORY ANALYSIS
TABLE 13 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.7 VALUE CHAIN ANALYSIS
FIGURE 19 VALUE CHAIN ANALYSIS OF RNA THERAPEUTICS MARKET: R&D AND MANUFACTURING PHASES ADD MAXIMUM VALUE
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 20 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.9 KEY STAKEHOLDERS AND BUYING CRITERIA
5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RNA-BASED THERAPEUTICS
5.9.2 BUYING CRITERIA FOR RNA THERAPEUTIC PRODUCTS/MEDICINES
FIGURE 22 KEY BUYING CRITERIA FOR END USERS
5.10 PRICING ANALYSIS
5.10.1 PRICING ANALYSIS FOR FDA-APPROVED RNA THERAPEUTICS, BY PRODUCT
TABLE 17 AVERAGE SELLING PRICE FOR RNA VACCINES AND DRUGS, BY REGION
5.10.2 PRICING TREND ANALYSIS: RNA VACCINES AND DRUGS
5.11 KEY CONFERENCES AND EVENTS (2023–2024)
TABLE 18 KEY CONFERENCES AND EVENTS IN RNA THERAPEUTICS MARKET (2023–2024)
5.12 ECOSYSTEM MARKET MAP
6 RNA THERAPEUTICS MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 19 RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
6.2 VACCINES
6.2.1 INCREASED NUMBER OF APPROVALS AND HIGHER INVESTMENTS FOR COVID-19 BOOSTER VACCINES TO DRIVE MARKET
TABLE 20 RNA THERAPEUTICS MARKET FOR VACCINES, BY REGION, 2021–2028 (USD MILLION)
TABLE 21 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 22 EUROPE: RNA THERAPEUTICS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 23 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
6.3 DRUGS
6.3.1 GROWING FUNDING AND INVESTMENTS IN RNA THERAPEUTICS RESEARCH TO DRIVE MARKET
TABLE 24 RNA THERAPEUTICS MARKET FOR DRUGS, BY REGION, 2021–2028 (USD MILLION)
TABLE 25 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 26 EUROPE: RNA THERAPEUTICS MARKET FOR DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 27 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)
7 RNA THERAPEUTICS MARKET, BY TYPE
7.1 INTRODUCTION
TABLE 28 RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION)
7.2 MRNA THERAPEUTICS
7.2.1 INCREASING INVESTMENTS FOR COVID-19 MRNA VACCINES TO DRIVE MARKET
TABLE 29 RNA THERAPEUTICS MARKET FOR MRNA THERAPEUTICS, BY REGION, 2021–2028 (USD MILLION)
TABLE 30 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR MRNA THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 31 EUROPE: RNA THERAPEUTICS MARKET FOR MRNA THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 32 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR MRNA THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION)
7.3 RNA INTERFERENCE (RNAI) THERAPEUTICS
7.3.1 INCREASING NUMBER OF APPROVALS FOR SIRNA THERAPEUTICS BY US FDA TO DRIVE MARKET
TABLE 33 RNA THERAPEUTICS MARKET FOR RNA INTERFERENCE (RNAI) THERAPEUTICS, BY REGION, 2021–2028 (USD MILLION)
TABLE 34 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR RNA INTERFERENCE (RNAI) THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 35 EUROPE: RNA THERAPEUTICS MARKET FOR RNA INTERFERENCE (RNAI) THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 36 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR RNA INTERFERENCE (RNAI) THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION)
7.4 ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS
7.4.1 INCREASED NUMBER OF CHEMICAL MODIFICATIONS AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
TABLE 37 RNA THERAPEUTICS MARKET FOR ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS, BY REGION, 2021–2028 (USD MILLION)
TABLE 38 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 39 EUROPE: RNA THERAPEUTICS MARKET FOR ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 40 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION)
7.5 OTHER THERAPEUTICS
8 RNA THERAPEUTICS MARKET, BY INDICATION
8.1 INTRODUCTION
TABLE 41 RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
8.2 INFECTIOUS DISEASES
8.2.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES AND GROWING INVESTMENTS IN R&D TO DRIVE MARKET
TABLE 42 RNA THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION)
TABLE 43 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 44 EUROPE: RNA THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 45 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
8.3 RARE GENETIC/HEREDITARY DISEASES
8.3.1 TECHNOLOGICAL INNOVATION AND INCREASED DEMAND FOR PERSONALIZED MEDICINES TO DRIVE MARKET
TABLE 46 RNA THERAPEUTICS MARKET FOR RARE GENETIC/HEREDITARY DISEASES, BY REGION, 2021–2028 (USD MILLION)
TABLE 47 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR RARE GENETIC/HEREDITARY DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 48 EUROPE: RNA THERAPEUTICS MARKET FOR RARE GENETIC/HEREDITARY DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 49 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR RARE GENETIC/HEREDITARY DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
8.4 OTHER INDICATIONS
TABLE 50 RNA THERAPEUTICS MARKET FOR OTHER INDICATIONS, BY REGION, 2021–2028 (USD MILLION)
TABLE 51 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 52 EUROPE: RNA THERAPEUTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 53 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
9 RNA THERAPEUTICS MARKET, BY END USER
9.1 INTRODUCTION
TABLE 54 RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
9.2 HOSPITALS AND CLINICS
9.2.1 INCREASED PREVALENCE OF CHRONIC DISEASES AND HIGHER EFFICACY OF RNA-BASED THERAPIES TO DRIVE MARKET
TABLE 55 RNA THERAPEUTICS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021–2028 (USD MILLION)
TABLE 56 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 57 EUROPE: RNA THERAPEUTICS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 58 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)
9.3 RESEARCH SETTINGS
9.3.1 HIGHER THERAPEUTIC POTENTIAL OF RNA TECHNOLOGY TO CREATE NEW OPPORTUNITIES IN MEDICAL RESEARCH
TABLE 59 RNA THERAPEUTICS MARKET FOR RESEARCH SETTINGS, BY REGION, 2021–2028 (USD MILLION)
TABLE 60 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR RESEARCH SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 61 EUROPE: RNA THERAPEUTICS MARKET FOR RESEARCH SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 62 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR RESEARCH SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)
10 RNA THERAPEUTICS MARKET, BY REGION
10.1 INTRODUCTION
TABLE 63 RNA THERAPEUTICS MARKET, BY REGION, 2021–2028 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 23 NORTH AMERICA: RNA THERAPEUTICS MARKET SNAPSHOT
TABLE 64 NORTH AMERICA: RNA THERAPEUTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 65 NORTH AMERICA: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 66 NORTH AMERICA: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 67 NORTH AMERICA: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 68 NORTH AMERICA: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.1 NORTH AMERICA: RECESSION IMPACT
10.2.2 US
10.2.2.1 Growing technological innovation in RNA delivery systems and rising investments in biopharmaceutical research to drive market
TABLE 69 LIST OF RECENT RNA THERAPEUTICS APPROVED BY FDA
TABLE 70 US: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 71 US: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 72 US: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 73 US: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.3 CANADA
10.2.3.1 Increasing government initiatives and investments for life science research to drive market
TABLE 74 CANADA: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 75 CANADA: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 76 CANADA: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 77 CANADA: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3 EUROPE
TABLE 78 EUROPE: RNA THERAPEUTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 79 EUROPE: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 80 EUROPE: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 81 EUROPE: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 82 EUROPE: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.1 EUROPE: RECESSION IMPACT
10.3.2 GERMANY
10.3.2.1 Rising number of market players and growing public and private funding for research activities to drive market
TABLE 83 GERMANY: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 84 GERMANY: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 85 GERMANY: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 86 GERMANY: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Growing pharmaceutical manufacturing industry and increasing number of clinical trials for oncology to drive market
TABLE 87 FRANCE: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 88 FRANCE: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 89 FRANCE: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 90 FRANCE: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.4 UK
10.3.4.1 Higher R&D investment by pharmaceutical companies for RNA-based drug discovery to drive market
TABLE 91 UK: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 92 UK: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 93 UK: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 94 UK: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.5 REST OF EUROPE
TABLE 95 REST OF EUROPE: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 96 REST OF EUROPE: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 97 REST OF EUROPE: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 98 REST OF EUROPE: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 24 ASIA PACIFIC: RNA THERAPEUTICS MARKET SNAPSHOT
TABLE 99 ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 100 ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 101 ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 102 ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 103 ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.1 ASIA PACIFIC: RECESSION IMPACT
10.4.2 JAPAN
10.4.2.1 Increasing geriatric population and rising government initiatives for drug innovation to drive market
TABLE 104 JAPAN: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 105 JAPAN: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 106 JAPAN: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 107 JAPAN: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.3 CHINA
10.4.3.1 Low manufacturing costs and increased number of R&D activities to drive market
TABLE 108 CHINA: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 109 CHINA: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 110 CHINA: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 111 CHINA: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.4 SOUTH KOREA
10.4.4.1 Increasing number of government initiatives and growing R&D activities for RNA therapeutics to drive market
TABLE 112 SOUTH KOREA: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 113 SOUTH KOREA: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 114 SOUTH KOREA: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 115 SOUTH KOREA: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.5 REST OF ASIA PACIFIC
TABLE 116 REST OF ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 117 REST OF ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 118 REST OF ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 119 REST OF ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.5 REST OF THE WORLD
TABLE 120 REST OF THE WORLD: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 121 REST OF THE WORLD: RNA THERAPEUTICS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 122 REST OF THE WORLD: RNA THERAPEUTICS MARKET, BY INDICATION, 2021–2028 (USD MILLION)
TABLE 123 REST OF THE WORLD: RNA THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS IN RNA THERAPEUTICS MARKET
FIGURE 25 KEY PLAYER STRATEGIES IN RNA THERAPEUTICS MARKET, 2021–2023
11.3 MARKET SHARE ANALYSIS
FIGURE 26 MARKET SHARE ANALYSIS OF TOP 3 PLAYERS IN RNA THERAPEUTICS MARKET, 2022
TABLE 124 DEGREE OF COMPETITION: RNA THERAPEUTICS MARKET
11.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 27 REVENUE SHARE ANALYSIS OF TOP 4 PLAYERS IN RNA THERAPEUTICS MARKET, 2020–2022
11.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 28 COMPANY EVALUATION MATRIX FOR KEY PLAYERS: RNA THERAPEUTICS MARKET, 2022
11.6 COMPANY EVALUATION MATRIX FOR START-UPS/SMES
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 DYNAMIC COMPANIES
11.6.4 RESPONSIVE COMPANIES
FIGURE 29 COMPANY EVALUATION MATRIX FOR START-UPS/SMES: RNA THERAPEUTICS MARKET, 2022
11.7 COMPETITIVE BENCHMARKING
TABLE 125 DETAILED LIST OF KEY START-UPS/SMES: RNA THERAPEUTICS MARKET
11.8 COMPETITIVE SCENARIOS AND TRENDS
11.8.1 KEY PRODUCT APPROVALS
TABLE 126 KEY PRODUCT APPROVALS, JANUARY 2021–AUGUST 2023
11.8.2 KEY DEALS
TABLE 127 KEY DEALS, JANUARY 2021–AUGUST 2023
11.8.3 OTHER KEY DEVELOPMENTS
TABLE 128 OTHER KEY DEVELOPMENTS, JANUARY 2021–AUGUST 2023
12 COMPANY PROFILES
(Business overview, Products offered, Recent Developments, MNM view)*
12.1 KEY PLAYERS
12.1.1 MODERNA, INC.
TABLE 129 MODERNA, INC.: COMPANY OVERVIEW
FIGURE 30 MODERNA, INC.: COMPANY SNAPSHOT (2022)
12.1.2 ALNYLAM PHARMACEUTICALS, INC.
TABLE 130 ALNYLAM PHARMACEUTICALS, INC.: COMPANY OVERVIEW
FIGURE 31 ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2022)
12.1.3 NOVARTIS AG
TABLE 131 NOVARTIS AG: COMPANY OVERVIEW
FIGURE 32 NOVARTIS AG: COMPANY SNAPSHOT (2022)
12.1.4 IONIS PHARMACEUTICALS, INC.
TABLE 132 IONIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW
FIGURE 33 IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2022)
12.1.5 SAREPTA THERAPEUTICS, INC.
TABLE 133 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW
FIGURE 34 SAREPTA THERAPEUTICS, INC.: COMPANY SNAPSHOT (2022)
12.1.6 SANOFI
TABLE 134 SANOFI: COMPANY OVERVIEW
FIGURE 35 SANOFI: COMPANY SNAPSHOT (2022)
12.1.7 PFIZER INC.
TABLE 135 PFIZER INC.: COMPANY OVERVIEW
FIGURE 36 PFIZER INC.: COMPANY SNAPSHOT (2022)
12.2 OTHER PLAYERS
12.2.1 ARROWHEAD PHARMACEUTICALS, INC.
12.2.2 BIONTECH SE
12.2.3 ORNA THERAPEUTICS
12.2.4 CRISPR THERAPEUTICS
12.2.5 SILENCE THERAPEUTICS
12.2.6 ASTELLAS PHARMA INC.
12.2.7 CUREVAC SE
12.2.8 SIRNAOMICS
12.2.9 ARCTURUS THERAPEUTICS, INC.
12.2.10 ARBUTUS BIOPHARMA
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
13 APPENDIX
13.1 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.2 CUSTOMIZATION OPTIONS
13.3 RELATED REPORTS
13.4 AUTHOR DETAILS
